Guggenheim Capital LLC Buys 82,394 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)

Guggenheim Capital LLC lifted its holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 341.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 106,538 shares of the company's stock after purchasing an additional 82,394 shares during the quarter. Guggenheim Capital LLC's holdings in Dr. Reddy's Laboratories were worth $1,682,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the stock. Promethos Capital LLC boosted its position in shares of Dr. Reddy's Laboratories by 402.6% during the 4th quarter. Promethos Capital LLC now owns 677,184 shares of the company's stock valued at $10,693,000 after purchasing an additional 542,450 shares in the last quarter. Causeway Capital Management LLC grew its position in Dr. Reddy's Laboratories by 400.0% in the fourth quarter. Causeway Capital Management LLC now owns 539,305 shares of the company's stock worth $8,516,000 after buying an additional 431,444 shares during the last quarter. Mariner LLC increased its holdings in shares of Dr. Reddy's Laboratories by 479.7% in the fourth quarter. Mariner LLC now owns 138,375 shares of the company's stock valued at $2,185,000 after buying an additional 114,504 shares in the last quarter. Townsquare Capital LLC lifted its position in shares of Dr. Reddy's Laboratories by 394.9% during the 4th quarter. Townsquare Capital LLC now owns 17,833 shares of the company's stock valued at $282,000 after acquiring an additional 14,230 shares during the last quarter. Finally, Qtron Investments LLC boosted its position in shares of Dr. Reddy's Laboratories by 178.6% in the 4th quarter. Qtron Investments LLC now owns 13,982 shares of the company's stock valued at $221,000 after purchasing an additional 8,963 shares during the period. Institutional investors and hedge funds own 3.85% of the company's stock.

Dr. Reddy's Laboratories Trading Down 1.5 %

Shares of RDY traded down $0.21 during midday trading on Wednesday, hitting $13.68. The stock had a trading volume of 2,969,385 shares, compared to its average volume of 1,461,058. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. The firm has a market cap of $11.42 billion, a P/E ratio of 21.78 and a beta of 0.51. Dr. Reddy's Laboratories Limited has a fifty-two week low of $12.26 and a fifty-two week high of $16.89. The business has a 50-day simple moving average of $13.15 and a two-hundred day simple moving average of $14.25.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last released its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. As a group, equities analysts forecast that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current year.

Dr. Reddy's Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.